PETERS WILLIAM J sold $184K of AMPH

PETERS WILLIAM J (CFO, EVP & TREASURER) sold 8,180 shares of Amphastar Pharmaceuticals, Inc. (AMPH) at $22.48 ($0.18M total) on 2026-08-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · PETERS WILLIAM J
Published Aug 11, 2026, 8:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AMPH
Neutral
medium confidence
Mentioned
$AMPH
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMPHNeutralLow
01

Why it matters

The disclosure updates the record of insider ownership and may influence sentiment, but it does not introduce new company fundamentals (no guidance, trial results, or deal terms).

02

Market read

Traders may monitor AMPH for follow-on insider activity, but the 10b5-1 framing suggests the sale is likely planned rather than reactive.

03

What to watch

The article does not state whether the sale was part of a broader multi-tranche program, nor does it provide option exercises or other offsetting insider activity that could change net signaling.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-11, transaction dated 2026-08-07

Background

This is an SEC Form 4 insider transaction disclosure for Amphastar Pharmaceuticals, Inc. (AMPH).

Company-level read

Ticker impact

$AMPHNeutralMedium confidence
Context

Insider Form 4 shows AMPH CFO William J. Peters sold 8,180 shares on 2026-08-07 at $22.48 via a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a primary-source Form 4, but the presence of a pre-arranged 10b5-1 plan and the lack of any accompanying fundamental catalyst reduce directional conviction.

Market effects

No clear sector read-through from a single routine insider sale at a biotech/pharma company.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling by senior executives can still be interpreted as a lack of near-term upside conviction by the market.

Key entities

  • Amphastar Pharmaceuticals, Inc.

    Subject of the Form 4 insider sale disclosure.

  • William J. Peters

    CFO, EVP & Treasurer who sold shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AMPHHigh

Amphastar (AMPH) Q3 2026 Earnings Call Transcript

Amphastar (AMPH) reported Q3 2026 revenue of $207.6M, up 8% YoY, driven by BAQSIMI and Primatene MIST sales. Gross margin fell to 48% due to pricing pressures and IMS facility remediation costs. EPS rose to $1.14. The company increased its share buyback program by $50M and expects high single-digit Q4 growth. IMS backlog stands at $12.5M due to operational constraints. Insulin aspart launch is targeted for 2027, pending FDA approval.

$AMPHHighAI 8/10

Amphastar Pharmaceuticals Inc (AMPH) Q3 2026 Earnings Call Highlights: Record Revenue

Amphastar Pharmaceuticals reported Q3 2026 revenue of $207.6M, up 8% YoY, with adjusted EPS of $1.14. CFO Bill Peters addressed pricing headwinds, IMS remediation costs, and growth drivers like Baximi and Primatene Mist. The company expects continued lidocaine demand but constrained capacity. Insulin biosimilar launches are planned for 2027, with margin normalization dependent on higher volumes. Q4 sales are expected to grow in the high single digits.

$AMPHMed

Amphastar Pharmaceuticals Q3 Earnings Call Highlights

Amphastar Pharmaceuticals reported Q3 gross margin decline to 48% from 51% YoY, citing lower pricing for BAQSIMI and increased manufacturing costs. The company expects higher remediation expenses in coming quarters. Amphastar aims to reduce a $12.5M backlog and sees continued lidocaine demand. It remains on track for potential 2027 launches of insulin aspart biosimilar and AMP-018, with other pipeline updates. Operating cash flow was $43.3M, and the board authorized $50M for share repurchases.